# Armando LÃ³pez-Guillermo

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 165 papers | 18,327 citations | 61857 43 h-index | 13338 130 g-index |
| 169 all docs | 169 docs citations | 169 times ranked | 15661 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. New England Journal of Medicine, 2002, 346, 1937-1947. | 13.9 | 3,474 |
| 2 | CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, The, 2006, 7, 379-391. | 5.1 | 1,840 |
| 3 | Follicular Lymphoma International Prognostic Index. Blood, 2004, 104, 1258-1265. | 0.6 | 1,552 |
| 4 | Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2018, 378, 1396-1407. | 13.9 | 1,443 |
| 5 | Adult haemophagocytic syndrome. Lancet, The, 2014, 383, 1503-1516. | 6.3 | 1,013 |
| 6 | Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, The, 2011, 377, 42-51. | 6.3 | 957 |
| 7 | Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature, 2015, 526, 519-524. | 13.7 | 749 |
| 8 | Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. Journal of Clinical Oncology, 2009, 27, 4555-4562. | 0.8 | 613 |
| 9 | The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253. | 0.6 | 512 |
| 10 | Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18250-18255. | 3.3 | 488 |
| 11 | Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. Cancer Research, 2010, 70, 1408-1418. | 0.4 | 429 |
| 12 | Mantle cell lymphoma. , 1998, 82, 567-575. | | 302 |
| 13 | Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. New England Journal of Medicine, 2018, 379, 934-947. | 13.9 | 264 |
| 14 | Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood, 2016, 127, 2122-2130. | 0.6 | 260 |
| 15 | Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. Journal of Clinical Oncology, 2005, 23, 2797-2804. | 0.8 | 253 |
| 16 | Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features. Cancer Research, 2012, 72, 5307-5316. | 0.4 | 231 |
| 17 | MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica, 2013, 98, 1554-1562. | 1.7 | 196 |
| 18 | Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. Journal of Clinical Oncology, 2019, 37, 2815-2824. | 0.8 | 173 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncology, The, 2018, 19, 549-561. | 5.1 | 165 |
| 20 | A MALT lymphoma prognostic index. Blood, 2017, 130, 1409-1417. | 0.6 | 149 |
| 21 | Follicular lymphoma. Nature Reviews Disease Primers, 2019, 5, 83. | 18.1 | 148 |
| 22 | Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematology,the, 2019, 6, e67-e78. | 2.2 | 146 |
| 23 | Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 1992, 81, 391-394. | 1.2 | 140 |
| 24 | Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood, 2020, 136, 1419-1432. | 0.6 | 131 |
| 25 | Characterization and risk estimate of cancer in patients with primary SjÃ¶gren syndrome. Journal of Hematology and Oncology, 2017, 10, 90. | 6.9 | 112 |
| 26 | Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica, 2014, 99, 1410-1420. | 1.7 | 103 |
| 27 | Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. Cancer Cell, 2016, 30, 806-821. | 7.7 | 103 |
| 28 | Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica, 2013, 98, 1014-1021. | 1.7 | 98 |
| 29 | Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood, 2014, 123, 3790-3796. | 0.6 | 97 |
| 30 | A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood, 2018, 132, 413-422. | 0.6 | 89 |
| 31 | Leukemic involvement is a common feature in mantle cell lymphoma. Cancer, 2007, 109, 2473-2480. | 2.0 | 82 |
| 32 | Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood, 2016, 128, 2666-2670. | 0.6 | 82 |
| 33 | Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood, 2020, 135, 274-286. | 0.6 | 81 |
| 34 | Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Annals of Hematology, 2015, 94, 803-812. | 0.8 | 74 |
| 35 | Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematology,the, 2018, 5, e359-e367. | 2.2 | 74 |
| 36 | Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes and Cancer, 2010, 49, 439-451. | 1.5 | 68 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Validation of the <scp>NCCN</scp>â€“<scp>IPI</scp> for diffuse large Bâ€cell lymphoma (<scp>DLBCL</scp>): the addition of Î²<sub>2</sub>â€microglobulin yields a more accurate <scp>GELTAMO</scp>â€“<scp>IPI</scp>. British Journal of Haematology, 2017, 176, 918-928. | 1.2 | 65 |
| 38 | Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. British Journal of Haematology, 2017, 178, 699-708. | 1.2 | 61 |
| 39 | HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. Modern Pathology, 2017, 30, 745-760. | 2.9 | 60 |
| 40 | Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. British Journal of Haematology, 1994, 88, 117-121. | 1.2 | 56 |
| 41 | MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. Clinical Cancer Research, 2016, 22, 2755-2764. | 3.2 | 55 |
| 42 | Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. Seminars in Arthritis and Rheumatism, 2016, 45, 391-399. | 1.6 | 52 |
| 43 | Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia. Blood, 2015, 126, 195-202. | 0.6 | 50 |
| 44 | Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. British Journal of Haematology, 2019, 184, 753-759. | 1.2 | 49 |
| 45 | Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood, 2022, 139, 732-747. | 0.6 | 49 |
| 46 | Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study. Clinical Cancer Research, 2021, 27, 513-521. | 3.2 | 45 |
| 47 | Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. , 1999, 189, 288-293. | | 44 |
| 48 | Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood, 2015, 126, 582-582. | 0.6 | 39 |
| 49 | The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemiaâ€“Microenvironment Interactions in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 1493-1505. | 3.2 | 38 |
| 50 | High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. Leukemia Research, 2017, 59, 20-25. | 0.4 | 35 |
| 51 | Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica, 2014, 99, e231-e234. | 1.7 | 33 |
| 52 | Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. Biology of Blood and Marrow Transplantation, 2017, 23, 1631-1640. | 2.0 | 32 |
| 53 | DEVELOPMENT OF AGGRESSIVE PLASMA CELL LEUKAEMIA UNDER INTERFERON-ALPHA THERAPY. British Journal of Haematology, 1991, 79, 523-525. | 1.2 | 29 |
| 54 | Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell deathâ€ligand 1 (PDâ€L1) axis in postâ€transplant lymphoproliferative disorders: association with Epsteinâ€“Barr virus, PDâ€L1 copy number alterations, and outcome. Histopathology, 2019, 75, 799-812. | 1.6 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica, 2020, 105, 2592-2597. | 1.7 | 29 |
| 56 | Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. Haematologica, 2017, 102, e360-e363. | 1.7 | 27 |
| 57 | Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. Journal of Clinical Oncology, 2022, 40, 1196-1205. | 0.8 | 27 |
| 58 | Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2016, 22, 6217-6227. | 3.2 | 26 |
| 59 | Life expectancy of follicular lymphoma patients in complete response at 30Âmonths is similar to that of the Spanish general population. British Journal of Haematology, 2019, 185, 480-491. | 1.2 | 26 |
| 60 | An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. European Journal of Haematology, 1996, 57, 286-291. | 1.1 | 24 |
| 61 | Disruption of Follicular Dendritic Cellsâ€“Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib). Clinical Cancer Research, 2014, 20, 3458-3471. | 3.2 | 24 |
| 62 | Lenalidomide in combination with Râ€‹<scp>ESHAP</scp> in patients with relapsed or refractory diffuse large Bâ€‹cell lymphoma: a phase 1b study from <scp>GELTAMO</scp> group. British Journal of Haematology, 2016, 173, 245-252. | 1.2 | 24 |
| 63 | Detection of chromothripsisâ€‹like patterns with a custom array platform for chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2015, 54, 668-680. | 1.5 | 23 |
| 64 | PI3KÎ´ inhibition reshapes follicular lymphomaâ€“immune microenvironment cross talk and unleashes the activity of venetoclax. Blood Advances, 2020, 4, 4217-4231. | 2.5 | 23 |
| 65 | Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. Blood Cancer Journal, 2020, 10, 31. | 2.8 | 23 |
| 66 | Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer, 2001, 91, 1557-1562. | 2.0 | 22 |
| 67 | In vivo intratumoral Epsteinâ€“Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. Modern Pathology, 2014, 27, 1599-1611. | 2.9 | 22 |
| 68 | SOX11, CD70, and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma. Blood, 2021, 138, 2202-2215. | 0.6 | 22 |
| 69 | RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. Annals of Hematology, 2020, 99, 799-808. | 0.8 | 21 |
| 70 | Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richterâ€™s Transformation. Frontiers in Oncology, 2022, 12, 828471. | 1.3 | 19 |
| 71 | Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148. | | 17 |
| 72 | Clinicoâ€‹biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. British Journal of Haematology, 2022, 196, 146-155. | 1.2 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. Leukemia and Lymphoma, 2011, 52, 1-14. | 0.6 | 16 |
| 74 | Increased tumour angiogenesis in SOX11â€positive mantle cell lymphoma. Histopathology, 2019, 75, 704-714. | 1.6 | 16 |
| 75 | Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. Hematological Oncology, 2018, 36, 765-772. | 0.8 | 15 |
| 76 | Past, present and future of prognostic scores in follicular lymphoma. Blood Reviews, 2021, 50, 100865. | 2.8 | 15 |
| 77 | Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. British Journal of Haematology, 2019, 184, 797-807. | 1.2 | 13 |
| 78 | Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric realâ€world study. Cancer Medicine, 2021, 10, 7629-7640. | 1.3 | 13 |
| 79 | Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Annals of Hematology, 2017, 96, 405-410. | 0.8 | 12 |
| 80 | Differential expression of long nonâ€coding <scp>RNA</scp>s are related to proliferation and histological diversity in follicular lymphomas. British Journal of Haematology, 2019, 184, 373-383. | 1.2 | 12 |
| 81 | Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. Cancers, 2021, 13, 3900. | 1.7 | 12 |
| 82 | Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. Blood, 2017, 130, 833-833. | 0.6 | 12 |
| 83 | Risk of relapse and clinicoâ€pathological features in 103 patients with diffuse largeâ€cell lymphoma in complete response after firstâ€line treatment. European Journal of Haematology, 1998, 61, 59-64. | 1.1 | 11 |
| 84 | Progressionâ€free survival at 2Âyears postâ€autologous transplant: a surrogate end point for overall survival in follicular lymphoma. Cancer Medicine, 2017, 6, 2766-2774. | 1.3 | 11 |
| 85 | Is there a role for minimal residual disease monitoring in the management of patients with hairyâ€cell leukaemia?. British Journal of Haematology, 2018, 183, 127-129. | 1.2 | 10 |
| 86 | A Cyclin D1â€“Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clinical Cancer Research, 2021, 27, 213-225. | 3.2 | 10 |
| 87 | A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma. Leukemia and Lymphoma, 2021, 62, 104-111. | 0.6 | 9 |
| 88 | RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R<sup>2</sup>) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.. Journal of Clinical Oncology, 2018, 36, 7500-7500. | 0.8 | 9 |
| 89 | Clinical impact of MYD88 mutations in chronic lymphocytic leukemia. Blood, 2016, 127, 1611-1613. | 0.6 | 8 |
| 90 | Non-Hodgkin's Lymphoma Following Untreated Essential Thrombocythemia. Leukemia and Lymphoma, 2000, 36, 421-423. | 0.6 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. Applied Health Economics and Health Policy, 2016, 14, 465-477. | 1.0 | 7 |
| 92 | Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12Âyears follow-up of a phase 2 trial. Annals of Hematology, 2017, 96, 639-646. | 0.8 | 7 |
| 93 | High serum levels of IL-2R, IL-6, and TNF-Î± are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era. Leukemia Research, 2020, 94, 106371. | 0.4 | 7 |
| 94 | HHV8-positive, EBV-positive Hodgkin lymphoma-like large B cell lymphoma: expanding the spectrum of HHV8 and EBV-associated lymphoproliferative disorders. International Journal of Hematology, 2020, 112, 734-740. | 0.7 | 7 |
| 95 | Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.. Journal of Clinical Oncology, 2021, 39, 7512-7512. | 0.8 | 7 |
| 96 | An old disease in an atypical place. Survey of Ophthalmology, 2014, 59, 660-663. | 1.7 | 6 |
| 97 | A novel clinicogenetic prognostic score for follicular lymphoma. Lancet Oncology, The, 2015, 16, 1011-1012. | 5.1 | 6 |
| 98 | T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome. Leukemia and Lymphoma, 2017, 58, 842-850. | 0.6 | 6 |
| 99 | Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry. Bone Marrow Transplantation, 2018, 53, 780-783. | 1.3 | 6 |
| 100 | Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia. Blood Cancer Journal, 2018, 8, 10. | 2.8 | 6 |
| 101 | Prognostic ability of five clinical risk scores in follicular lymphoma: A singleâ€center evaluation. Hematological Oncology, 2021, 39, 639-649. | 0.8 | 6 |
| 102 | Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma. Diagnostics, 2022, 12, 1575. | 1.3 | 6 |
| 103 | The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 2318-2326. | 0.6 | 5 |
| 104 | Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma. British Journal of Haematology, 2021, 193, 299-306. | 1.2 | 5 |
| 105 | A randomized phase II study comparing consolidation with a single dose of <sup>90</sup>Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. Leukemia and Lymphoma, 2022, 63, 93-100. | 0.6 | 5 |
| 106 | Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial. Blood, 2019, 134, 752-752. | 0.6 | 5 |
| 107 | Patients with Mature T-Cell Lymphoma Show High Relapse Rates after High Dose Therapy and Autologous Stem Cell Transplantation. Blood, 2008, 112, 774-774. | 0.6 | 5 |
| 108 | Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study. Blood, 2010, 116, 432-432. | 0.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Scleroderma Associated with Idiopathic Myelofibrosis. Leukemia and Lymphoma, 1990, 1, 153-155. | 0.6 | 4 |
| 110 | Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 194-203. | 0.6 | 4 |
| 111 | ActualizaciÃ³n en el diagnÃ³stico, pronÃ³stico y tratamiento del linfoma folicular. Medicina ClÃnica, 2021, 157, 440-448. | 0.3 | 4 |
| 112 | Clinical Characteristics and Outcome of a Large Series of Patients with Chronic Lymphocytic Leukemia (CLL) According to ZAP-70 Expression.. Blood, 2004, 104, 14-14. | 0.6 | 4 |
| 113 | Novel Putative Driver Gene Mutations in Chronic Lymphocytic Leukemia (CLL): Results from a Combined Analysis of Whole-Exome Sequencing of 262 Primary CLL Samples. Blood, 2014, 124, 1952-1952. | 0.6 | 4 |
| 114 | Revised International Prognostic Index and genetic alterations are associated with early failure to Râ€CHOP in patients with diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2022, 196, 589-598. | 1.2 | 4 |
| 115 | Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases. Blood, 2014, 124, 1677-1677. | 0.6 | 4 |
| 116 | The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma. Leukemia and Lymphoma, 2022, 63, 903-910. | 0.6 | 4 |
| 117 | Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).. Journal of Clinical Oncology, 2022, 40, 7565-7565. | 0.8 | 4 |
| 118 | Is Good Clinical Practice Becoming Poor Clinical Care?. HemaSphere, 2017, 1, e4. | 1.2 | 3 |
| 119 | Evaluation of the MD Anderson tumor score for diffuse large Bâ€cell lymphoma in the rituximab era. European Journal of Haematology, 2020, 104, 400-408. | 1.1 | 3 |
| 120 | Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma. Annals of Hematology, 2021, 100, 1231-1239. | 0.8 | 3 |
| 121 | Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-Î²B blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation. Haematologica, 2021, 106, 2749-2753. | 1.7 | 3 |
| 122 | Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. Blood, 2019, 134, 1524-1524. | 0.6 | 3 |
| 123 | Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.. Blood, 2010, 116, 1788-1788. | 0.6 | 3 |
| 124 | A Phase 2 Study from Spanish Geltamo Group Investigating the Efficacy and Safety of Bendamustine As Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphomas: Second Interim Analysis. Blood, 2014, 124, 2524-2524. | 0.6 | 3 |
| 125 | Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo. Blood, 2016, 128, 4201-4201. | 0.6 | 3 |
| 126 | Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).. Journal of Clinical Oncology, 2017, 35, TPS7575-TPS7575. | 0.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance. Blood, 2021, 138, 2417-2417. | 0.6 | 3 |
| 128 | Chronic lymphocytic leukaemia and prolymphocytic leukaemia. Two coins or two sides of the same coin?. Haematologica, 2020, 105, e484. | 1.7 | 2 |
| 129 | An IELSG International Survey of Primary Effusion Lymphoma (PEL).. Blood, 2004, 104, 3265-3265. | 0.6 | 2 |
| 130 | Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group. Blood, 2015, 126, 3944-3944. | 0.6 | 2 |
| 131 | Serum monoclonal component in chronic lymphocytic leukemia: baseline correlations and prognostic impact. Haematologica, 2021, 106, 1754-1757. | 1.7 | 2 |
| 132 | Genetic evolution in chronic lymphocytic leukaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 67-78. | 0.7 | 1 |
| 133 | The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. European Journal of Haematology, 2021, 106, 428-432. | 1.1 | 1 |
| 134 | Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era. Blood, 2017, 130, 827-827. | 0.6 | 1 |
| 135 | A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma. Blood, 2021, 138, 4362-4362. | 0.6 | 1 |
| 136 | The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726. | 1.2 | 1 |
| 137 | NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12. Genes Chromosomes and Cancer, 2012, 51, 1064-1065. | 1.5 | 0 |
| 138 | Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 482-485. | 0.6 | 0 |
| 139 | Minimal residual disease â€“ ready for prime time in follicular lymphoma?. British Journal of Haematology, 2020, 188, 205-206. | 1.2 | 0 |
| 140 | Recent Advancements in Hematology: Knowledge, Methods and Dissemination. Hemato, 2020, 1, 5-6. | 0.2 | 0 |
| 141 | Response to: The lymphocyte-to-monocyte ratio in follicular lymphoma. Leukemia and Lymphoma, 2021, 62, 1-2. | 0.6 | 0 |
| 142 | Effect of Germline Polymorphisms on Clinical Outcome in Hodgkinâ€™s Lymphoma (HL).. Blood, 2006, 108, 2267-2267. | 0.6 | 0 |
| 143 | Analysis of microRNA Patterns in Hodgkinâ€™s Lymphoma (HL).. Blood, 2006, 108, 474-474. | 0.6 | 0 |
| 144 | Activation of the Endoplasmic Reticulum (ER) Unfolded Protein Response (UPR) in Aggressive B-Cell Lymphomas.. Blood, 2006, 108, 2038-2038. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | IELSG Phase II Studies of Bortezomib in Malt Lymphomas.. Blood, 2007, 110, 2580-2580. | 0.6 | 0 |
| 146 | Mir-135a Expression Is Associated with Relapse in Hodgkin Lymphoma.. Blood, 2007, 110, 2270-2270. | 0.6 | 0 |
| 147 | Allogeneic Stem Cell Transplantation Results in a Low Relapse Rate in Patients with Peripheral T-Cell Lymphoma.. Blood, 2008, 112, 974-974. | 0.6 | 0 |
| 148 | T-Cell Subpopulations Quantified by Flow Cytometry in Lymph Node Cell Suspensions Identify a Group of Patients with Follicular Lymphoma with Good Prognosis.. Blood, 2009, 114, 1945-1945. | 0.6 | 0 |
| 149 | Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 4134-4134. | 0.6 | 0 |
| 150 | Lenalidomide In Combination With R-ESHAP (LR-ESHAP) In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Candidates To Autologous Stem-Cell Transplantation: A Phase 1b Study From Spanish Group Geltamo. Blood, 2013, 122, 4391-4391. | 0.6 | 0 |
| 151 | Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms. Blood, 2015, 126, 3902-3902. | 0.6 | 0 |
| 152 | Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients. Blood, 2015, 126, 521-521. | 0.6 | 0 |
| 153 | Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project. Blood, 2015, 126, 3955-3955. | 0.6 | 0 |
| 154 | Central Review of PET/TC: First Spanish Experience in a Phase 2 Randomized Trial in Diffuse Large B-Cell Lymphoma (DLBCL) Patients. Blood, 2015, 126, 5042-5042. | 0.6 | 0 |
| 155 | Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis. Blood, 2015, 126, 1514-1514. | 0.6 | 0 |
| 156 | Incidence and Prognostic Impact of Secondary Neoplasia after High Dose Therapy Supported By Autologous Stem Cell Transplantation in Follicular Lymphoma. a Long Term Follow-up Analysis from the Geltamo Registry. Blood, 2016, 128, 3451-3451. | 0.6 | 0 |
| 157 | Clinical Impact of the Quantitative Subclonal Architecture in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 2024-2024. | 0.6 | 0 |
| 158 | ÎFÎšÎ'Î™Î• Deletions: A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma. Blood, 2016, 128, 609-609. | 0.6 | 0 |
| 159 | Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study. Blood, 2018, 132, 4199-4199. | 0.6 | 0 |
| 160 | Early progression of disease (POD24) as survival predictor in MALT lymphoma.. Journal of Clinical Oncology, 2019, 37, 7548-7548. | 0.8 | 0 |
| 161 | First external validation of the FLIPIâ€Ł score in a singleâ€cenˆter series of patients with follicular lymphoma. Hematological Oncology, 2022, 40, 297-301. | 0.8 | 0 |
| 162 | Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo. Blood, 2021, 138, 2497-2497. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Infection Risk in Lymphoproliferative Diseases (LPD) Treated with Targeted Drugs. Geltamo Real-Life Experience. Blood, 2020, 136, 37-40. | 0.6 | 0 |
| 164 | Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 588-595. | 0.8 | 0 |
| 165 | Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial.. Journal of Clinical Oncology, 2022, 40, 7517-7517. | 0.8 | 0 |